Versione italiana

News - January 2010

Genovax is pleased to announce that has started the selection of patients for the Phase I clinical study of its project GX301.

GX301 is a project aiming at the clinical development of a vaccine against telomerase. In December 2009 the Italian “Istituto Superiore di Sanità”, the scientific body responsible for Phase I studies approvals, granted the authorization for the Phase I clinical study, which was already approved by Ethics Committee of San Martino University Hospital in Genova. GX301 vaccine is based on four peptides invented by Genovax researchers and it is covered by international patents: it will be studied in patients affected by renal and prostate carcinoma.

January 2010

a
 
Copyright © 2008-2022 Genovax S.r.l. - P.IVA 09820670017 - Camera di commercio di Torino n. 1083695 - Capitale sociale 15.000,00 euro
Web Design by Web & Com